Completed PHASE1 INTERVENTIONAL 1-arm NCT01761123

Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum (ICC H1)

An Open Label Phase I Substudy to Evaluate the Safety and Ability to Enhance Immunogenicity of VXA-A1.1 by Delivery Directly to the Ileum Using the InteliSite Companion Capsule in Healthy Adult Males

Sponsor: Vaxart

Conditions Seasonal Influenza

Interventions VXA-A1.1

Updated 6 times since 2017 Last updated: Dec 8, 2014 Started: Jan 31, 2013 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Seasonal Influenza and is currently completed. Vaxart leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vaxart

Data source: Vaxart

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lexington, United States